Robert G. Hunter, M.D.
About Robert G. Hunter, M.D.
Independent director of Security National Financial Corporation (SNFCA) since 1998; age 65 as of the 2025 proxy nominees list . Practicing otolaryngologist with leadership roles at Intermountain Medical Center (former Department Head of Otolaryngology for 10 years; past President of the medical staff), adjunct clinical Professor of Surgery at the University of Utah School of Medicine, and delegate roles to the Utah Medical Association and the American Medical Association . Education: B.S. in Microbiology and M.D. from the University of Utah; residency at the University of Texas, San Antonio .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Intermountain Medical Center | Department Head, Otolaryngology, Head & Neck Surgery; past President, medical staff | Department Head for 10 years (historical) | Led clinical department; hospital leadership engagement |
| University of Utah School of Medicine | Adjunct Clinical Professor of Surgery | Not disclosed | Academic instruction/clinical training |
| Utah Medical Association | Delegate | Not disclosed | Professional representation |
| American Medical Association | Delegate representing State of Utah | Not disclosed | National policy engagement |
| Rocky Mountain E.N.T., Inc. (statewide E.N.T. group) | Executive Committee member (historical disclosure) | Not disclosed | Group practice governance |
External Roles
| Organization | Role | Public Company? | Notes |
|---|---|---|---|
| — | — | — | No other public company directorships disclosed in SNFCA’s proxy biographies . |
Board Governance
| Item | Details |
|---|---|
| Independence | Board determined Dr. Hunter is independent under Nasdaq listing standards . |
| Board attendance | Board met 5 times in 2024; all directors attended every meeting except Ms. Love (missed one). Dr. Hunter attended all 5/5 . |
| Committees | Compensation Committee (member; all independent; met 3 times in 2024) . Nominating & Corporate Governance Committee (member; all independent; met 2 times in 2024) . Not on Audit (Fuller Chair) or Executive (Scott M. Quist Chair) . |
| Chair roles | None disclosed for Dr. Hunter (Compensation and Nominating chaired by H. Craig Moody; Audit chaired by Gilbert A. Fuller) . |
| Board leadership | CEO also serves as Chair; Board asserts independent directors meet in executive session. Lead director designated as H. Craig Moody for executive sessions of independent directors . |
Fixed Compensation (Director)
| Component | Amount/Policy | 2024 Dr. Hunter |
|---|---|---|
| Annual cash retainer | $43,200 per year ($3,600 monthly) for Outside Directors | $43,200 fees earned in cash |
| Meeting fees | Additional $750 per day for certain management meetings and each Audit Committee day | Not itemized (included in policy) |
| Retirement benefit | Upon Board retirement: one month director’s fee per year of service | Policy applies |
Performance Compensation (Director)
| Award Type | Standard Annual Grant | Additional 2024 Grant | 2024 Reported Value |
|---|---|---|---|
| Options or RSUs (director election) | 1,000 options OR 241 RSUs per year | 9,400 options OR 2,268 RSUs in 2024 | Option awards value $33,845 (Dr. Hunter) |
- Structure and metrics: Director equity awards are fixed grants (no disclosed performance metrics/TSR targets); vesting terms not specified for director grants in 2024 disclosure .
Other Directorships & Interlocks
| Company/Entity | Role | Overlap/Interlock risk |
|---|---|---|
| — | — | No public company directorships disclosed for Dr. Hunter; no disclosed business dealings between SNFCA and entities controlled by Dr. Hunter . |
Expertise & Qualifications
- Clinical and administrative leadership in healthcare (Intermountain Medical Center; academic adjunct professorship) .
- Governance experience from long SNFCA board tenure since 1998 .
- Professional society engagement (Utah Medical Association; AMA) .
Equity Ownership
| Holder | Class A Beneficial Ownership | Class C Beneficial Ownership | Notes |
|---|---|---|---|
| Robert G. Hunter, M.D. | 69,230 (<1%) | — | Footnote clarifies this includes options to purchase 69,230 Class A shares currently exercisable . No pledging disclosed. |
Say-on-Pay & Shareholder Feedback (Context)
| Proposal (2023 Annual Meeting) | Votes For | Votes Against | Abstain |
|---|---|---|---|
| Advisory vote on NEO compensation | 38,991,463 | 539,876 | 20,682 |
- Board notes will continue to monitor shareholder feedback on compensation cadence (every three years approved) .
Related Party Transactions (Conflict Screen)
- Proxy lists related person transactions involving CEO’s sons (S. Andrew Quist, Adam G. Quist) and nephew (Jason G. Overbaugh), with 2024 total compensation for each; Audit Committee reviewed and deemed reasonable and fair to the Company . No transactions disclosed involving Dr. Hunter or his family .
Insider Trades / Section 16 Compliance
| Person | 2024 Section 16 status |
|---|---|
| Robert G. Hunter, M.D. | One inadvertent late Form 4 filing reported for 2024 . |
Compensation Committee Analysis (Context)
- Compensation Committee composed solely of independent directors (includes Dr. Hunter) .
- No external consultant retained for the 2022 Equity Incentive Plan amendment (context on equity usage; not a director-specific grant) .
Governance Assessment
-
Positives:
- Independent director with 100% Board attendance in 2024, and service on two key independent committees (Compensation; Nominating & Corporate Governance) .
- Medical/administrative expertise and long tenure provide institutional knowledge; no disclosed related-party transactions involving Dr. Hunter .
- Director compensation structure modest with cash retainer plus annual equity; 2024 option award value of $33,845; cash fees $43,200 .
-
Watch items / RED FLAGS:
- Combined CEO/Chair structure; while a lead director is designated for executive sessions (H. Craig Moody), concentration of power at the top remains a governance consideration .
- One inadvertent late Section 16 filing by Dr. Hunter in 2024 (procedural compliance) .
- Broader company context includes significant family relationships among management (not involving Dr. Hunter), a recurring governance sensitivity investors often monitor .
-
Alignment:
- Beneficial ownership comprises currently exercisable options (69,230), aligning director incentives with equity value appreciation; percent ownership <1% suggests alignment is primarily through options rather than large outright holdings .
-
Engagement:
- Committee workloads: Compensation Committee (3 meetings in 2024) and Nominating & Governance (2 meetings in 2024) indicate active governance cadence; Dr. Hunter is a member of both .